

A Trial of Antiparasitic Treatment to Reduce the Rate of Cysticercosis

New England Journal of Medicine

350, 249-258

DOI: [10.1056/nejmoa031294](https://doi.org/10.1056/nejmoa031294)

Citation Report

#	ARTICLE	IF	CITATIONS
1	PARASITIC AND FUNGAL INFECTIONS. , 2000, , 1273-1295.		0
2	A Trial of Antiparasitic Treatment for Cerebral Cysticercosis. <i>New England Journal of Medicine</i> , 2004, 350, 1686-1687.	27.0	0
3	Neurocysticercosis " Is the Elimination of Parasites Beneficial?. <i>New England Journal of Medicine</i> , 2004, 350, 280-282.	27.0	28
4	Antiparasitic Therapy for Viable Cysts May Help Seizure Control in Patients with Neurocysticercosis. <i>Epilepsy Currents</i> , 2004, 4, 202-203.	0.8	0
5	Neurocysticercosis. <i>Epilepsy Currents</i> , 2004, 4, 107-111.	0.8	77
6	Anticysticercal treatment and seizures in neurocysticercosis. <i>Lancet Neurology</i> , The, 2004, 3, 207-208.	10.2	7
8	Differential Diagnosis Between Cerebral Tuberculosis and Neurocysticercosis by Magnetic Resonance Spectroscopy. <i>Journal of Computer Assisted Tomography</i> , 2005, 29, 112-114.	0.9	71
9	Neurocysticercosis: updated concepts about an old disease. <i>Lancet Neurology</i> , The, 2005, 4, 653-661.	10.2	468
10	Cysticercosis: Recent advances in diagnosis and management of neurocysticercosis. <i>Current Infectious Disease Reports</i> , 2005, 7, 39-47.	3.0	12
12	Proteomic analysis of a 120 kDa protein complex in cyst fluid of <i>Taenia solium</i> metacestode and preliminary evaluation of its value for the serodiagnosis of neurocysticercosis. <i>Parasitology</i> , 2005, 131, 867.	1.5	17
13	Parasitic Central Nervous System Infections in Immunocompromised Hosts. <i>Clinical Infectious Diseases</i> , 2005, 40, 1005-1015.	5.8	120
14	Neurocysticercosis. <i>Seminars in Neurology</i> , 2005, 25, 243-251.	1.4	84
15	<i>Taenia</i> (including cysticercosis) and hydatid disease. <i>Medicine</i> , 2005, 33, 70-73.	0.4	4
16	Antiparasitic Therapy in Children. <i>Pediatric Clinics of North America</i> , 2005, 52, 917-948.	1.8	33
17	Meta-Analysis: Cysticidal Drugs for Neurocysticercosis: Albendazole and Praziquantel. <i>Annals of Internal Medicine</i> , 2006, 145, 43.	3.9	194
18	Advances in the diagnosis and management of neurocysticercosis. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 1051-1061.	4.4	34
19	Clinical aspects of neurocysticercosis. <i>Parasitology International</i> , 2006, 55, S111-S115.	1.3	103
20	Progress in diagnosis, treatment and elimination of echinococcosis and cysticercosis. <i>Parasitology International</i> , 2006, 55, S7-S13.	1.3	66

#	ARTICLE	IF	CITATIONS
21	Neurocysticercosis: some of the essentials. <i>Practical Neurology</i> , 2006, 6, 288-297.	1.1	29
22	Efficacy of a 3-day course of albendazole treatment in patients with a single neurocysticercosis cyst. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 193-194.	1.4	24
23	Intravenous methyl prednisolone in patients with solitary cysticercus granuloma: A random evaluation. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2006, 15, 328-332.	2.0	22
24	The role of the irritative zone and of the number and distribution of calcifications in the severity of epilepsy associated with intracranial calcifications. <i>Arquivos De Neuro-Psiquiatria</i> , 2006, 64, 905-911.	0.8	17
26	Neurocysticercosis and Human Immunodeficiency Virus Infection: A Case Report. <i>Journal of Travel Medicine</i> , 2006, 13, 376-380.	3.0	15
27	Neurocysticercosis. <i>Current Infectious Disease Reports</i> , 2006, 8, 293-300.	3.0	11
28	Neurocysticercosis: Current knowledge and advances. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 453-459.	4.2	30
29	A membrane-associated metalloprotease of <i>Taenia solium</i> metacestode structurally related to the FACE-1/Ste24p protease family. <i>International Journal for Parasitology</i> , 2006, 36, 925-935.	3.1	10
30	Early recurrence of neurocysticercosis after orthotopic liver transplant. <i>Liver Transplantation</i> , 2006, 12, 490-491.	2.4	22
31	Treatment of neurocysticercosis: Current status and future research needs. <i>Neurology</i> , 2006, 67, 1120-1127.	1.1	167
32	Control of <i>Taenia solium</i> Cysticercosis/Taeniosis. <i>Advances in Parasitology</i> , 2006, 61, 509-566.	3.2	72
34	Cysteine Proteinase Inhibitors in Murine Cysticercosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2886-2888.	3.2	1
35	Does Albendazole Affect Seizure Remission and Computed Tomography Response in Children With Neurocysticercosis? A Systematic Review and Meta-analysis. <i>Journal of Child Neurology</i> , 2007, 22, 135-142.	1.4	14
36	Pulmonary and cardiac cysticercosis: helical CT findings. <i>British Journal of Radiology</i> , 2007, 80, e58-e60.	2.2	24
37	31 Antihelminthic drugs. <i>Side Effects of Drugs Annual</i> , 2007, 29, 320-326.	0.6	0
38	Do patients with neurocysticercosis benefit from cysticidal therapy?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 22-23.	2.5	1
39	Zoonotic helminth infections of humans: echinococcosis, cysticercosis and fascioliasis. <i>Current Opinion in Infectious Diseases</i> , 2007, 20, 489-494.	3.1	88
40	Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: An 8 year randomised study. <i>Journal of Clinical Neuroscience</i> , 2007, 14, 1172-1177.	1.5	44

#	ARTICLE	IF	CITATIONS
41	Gastrointestinal Parasite. Journal of Emergency Medicine, 2007, 33, 277-280.	0.7	0
42	<i>Taenia solium</i> Neurocysticercosis. New England Journal of Medicine, 2007, 357, 1666-1667.	27.0	7
43	A hydrophobic ligand-binding protein of the <i>Taenia solium</i> metacestode mediates uptake of the host lipid: Implication for the maintenance of parasitic cellular homeostasis. Proteomics, 2007, 7, 4016-4030.	2.2	38
44	Unusual presentations of neurocysticercosis. Acta Neurologica Scandinavica, 2007, 115, 192-198.	2.1	16
45	Human cysticercosis and Indian scenario: a review. Journal of Biosciences, 2008, 33, 571-582.	1.1	112
46	ELISA in the evaluation of therapeutic response to albendazole in neurocysticercosis. Journal of Infection, 2008, 56, 65-73.	3.3	6
47	The effects of antimicrobial and antiepileptic treatment on the outcome of epilepsy associated with central nervous system (CNS) infections. Epilepsia, 2008, 49, 42-46.	5.1	8
48	Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis: a prospective cohort and nested case-control study. Lancet Neurology, The, 2008, 7, 1099-1105.	10.2	176
52	Treatment of neurocysticercosis: is it beneficial?. Expert Review of Anti-Infective Therapy, 2008, 6, 435-440.	4.4	4
53	The Neurological Manifestations of Pediatric Infectious Diseases and Immunodeficiency Syndromes. , 2008, , .		1
54	Antiparasitic drugs in neurocysticercosis: albendazole or praziquantel?. Expert Review of Anti-Infective Therapy, 2008, 6, 295-298.	4.4	12
55	Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1050-1055.	1.9	133
56	Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 272-275.	1.9	39
57	Medical Treatment for Neurocysticercosis: Drugs, Indications and Perspectives. Current Topics in Medicinal Chemistry, 2008, 8, 424-433.	2.1	30
59	Helminthic Diseases: Taeniasis and Cysticercosis. , 2008, , 361-368.		0
60	A Case of Extensive Spinal Cysticercosis Involving the Whole Spinal Canal in a Patient with a History of Cerebral Cysticercosis. Yonsei Medical Journal, 2009, 50, 582.	2.2	15
61	New Developments in the Management of Neurocysticercosis. Journal of Infectious Diseases, 2009, 199, 1261-1262.	4.0	22
63	Epilepsy and neurocysticercosis in sub-Saharan Africa. Wiener Klinische Wochenschrift, 2009, 121, 3-12.	1.9	37

#	ARTICLE	IF	CITATIONS
64	Neurocysticercosis in children. Indian Journal of Pediatrics, 2009, 76, 537-545.	0.8	47
65	Epilepsy in the developing world. Current Neurology and Neuroscience Reports, 2009, 9, 319-326.	4.2	82
66	The Nepalese Shepherd. Journal of Travel Medicine, 2009, 16, 68-71.	3.0	3
67	Recognizing and Reducing the Risks of Helminthic Eosinophilic Meningitis in Travelers: Differential Diagnosis, Disease Management, Prevention, and Control. Journal of Travel Medicine, 2009, 16, 267-275.	3.0	15
68	Neurocysticercosis: A review of current status and management. Journal of Clinical Neuroscience, 2009, 16, 867-876.	1.5	133
69	Randomized controlled trial of albendazole in new onset epilepsy and MRI confirmed solitary cerebral cysticercal lesion: Effect on long-term seizure outcome. Journal of the Neurological Sciences, 2009, 276, 108-114.	0.6	21
71	Champ 4- recherche Étiologique lors d'un État de mal Épileptique. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2009, 18, 44-49.	0.1	1
72	Neurocysticercosis with a single brain lesion in Germany: a case report. Cases Journal, 2009, 2, 8692.	0.4	7
73	Mesocestoides corti intracranial infection as a murine model for neurocysticercosis. Parasitology, 2010, 137, 359-372.	1.5	44
74	Anthelmintics for people with neurocysticercosis. , 2010, , CD000215.		39
75	Neurocysticercosis: Changes after 25 Years of Medical Therapy. Archives of Medical Research, 2010, 41, 62-63.	3.3	18
76	Empiric albendazole therapy and new onset seizures A cautionary note. Journal of Infection, 2010, 60, 403-404.	3.3	12
77	Empiric albendazole therapy and eosinophilia recommendations a cautionary note. Journal of Infection, 2010, 60, 404-405.	3.3	1
78	Natural history of solitary cerebral cysticercosis cases after albendazole therapy: a longitudinal follow-up study from India. Acta Neurologica Scandinavica, 2010, 121, 204-208.	2.1	21
79	Reluctant hydrocephalus. Neuropathology, 2010, 30, 299-301.	1.2	0
80	Neuro and intraocular cysticercosis: A clinicopathological case report. Eye and Brain, 2010, , 39.	2.5	9
81	Antiparasitic agents. , 2010, , 1490-1507.		1
82	Exporting "failure": why research from rich countries may not benefit the developing world. Revista De Saude Publica, 2010, 44, 185-189.	1.7	47

#	ARTICLE	IF	CITATIONS
83	Evaluating the Efficacy of Teaching Methods Regarding Prevention of Human Epilepsy Caused by <i>Taenia solium</i> Neurocysticercosis in Western Kenya. <i>American Journal of Tropical Medicine and Hygiene</i> , 2010, 82, 634-642.	1.4	26
84	Bioactive molecules of <i>Taenia solium</i> metacestode, a causative agent of neurocysticercosis. <i>Expert Review of Proteomics</i> , 2010, 7, 691-707.	3.0	8
85	Neurocysticercosis. <i>Neurology</i> , 2010, 75, 654-658.	1.1	63
86	Solitary cysticercus granuloma-treatment with albendazole: What is the optimal duration?. <i>Neurology India</i> , 2010, 58, 507.	0.4	8
87	Clinico-radiological profile and treatment outcomes in neurocysticercosis: A study of 40 patients. <i>Annals of Tropical Medicine and Public Health</i> , 2010, 3, 58.	0.1	8
88	Comparison of 1 week versus 4 weeks of albendazole therapy in single small enhancing computed tomography lesion. <i>Neurology India</i> , 2010, 58, 560.	0.4	17
90	Natural history of solitary cerebral cysticercosis on serial magnetic resonance imaging and the effect of albendazole therapy on its evolution. <i>Journal of the Neurological Sciences</i> , 2010, 288, 135-141.	0.6	34
91	Anthelmintics for people with neurocysticercosis. , 2010, , CD000215.		36
92	Helminth Infections of the Central Nervous System Occurring in Southeast Asia and the Far East. <i>Advances in Parasitology</i> , 2010, 72, 351-408.	3.2	66
93	Neurocysticercosis in Qatari patients: Case reports. <i>Travel Medicine and Infectious Disease</i> , 2011, 9, 298-302.	3.0	17
94	Antiparasitic Therapy. <i>Mayo Clinic Proceedings</i> , 2011, 86, 561-583.	3.0	118
95	Neurocysticercosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 67-81.	3.5	57
96	Corticosteroid use in neurocysticercosis. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1175-1183.	2.8	51
97	Relevance of Neuroimaging in the Diagnosis and Management of Tropical Neurologic Disorders. <i>Neuroimaging Clinics of North America</i> , 2011, 21, 737-756.	1.0	6
98	Diagnosis and treatment of neurocysticercosis. <i>Nature Reviews Neurology</i> , 2011, 7, 584-594.	10.1	189
101	Cysticercosis of the central nervous system. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, 423-427.	3.1	42
102	Pharmacokinetics of combined treatment with praziquantel and albendazole in neurocysticercosis. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 77-84.	2.4	61
103	Infectious causes of seizures and epilepsy in the developing world. <i>Developmental Medicine and Child Neurology</i> , 2011, 53, 600-609.	2.1	105

#	ARTICLE	IF	CITATIONS
104	Reduction in rate of epilepsy from neurocysticercosis by community interventions: The SalamÃ¡j, Honduras Study. <i>Epilepsia</i> , 2011, 52, 1177-1185.	5.1	55
105	Neurocysticercosis in Travelers: A Nationâ€™Wide Study in Israel. <i>Journal of Travel Medicine</i> , 2011, 18, 191-197.	3.0	24
106	Medical management of neurocysticercosis. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2845-2856.	1.8	19
107	MÃ©decine tropicale et du voyage chez l'enfant. , 2011, , 541-566.		0
108	Cysticercosis. , 2011, , 815-823.		6
109	A Research Agenda for Helminth Diseases of Humans: Intervention for Control and Elimination. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1549.	3.0	163
110	Clinico-radiological profile and treatment outcomes in neurocysticercosis: A study of 40 patients. <i>Annals of Tropical Medicine and Public Health</i> , 2012, 5, 63.	0.1	0
111	A radiological case report on intraocular cysticercosis with associated vitreous detachment and neurocysticercosis. <i>Annals of Tropical Medicine and Public Health</i> , 2012, 5, 367.	0.1	1
112	Two Centuries of Neurology and Psychiatry in the <i>Journal</i>. <i>New England Journal of Medicine</i> , 2012, 367, 58-65.	27.0	5
113	Cognitive Changes and Quality of Life in Neurocysticercosis: A Longitudinal Study. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1493.	3.0	28
114	Neurocysticercosis. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2012, 18, 1392-1416.	0.8	16
115	What causes seizures in patients with calcified neurocysticercal lesions?. <i>Neurology</i> , 2012, 78, 612-613.	1.1	14
116	Solitary cysticercus granuloma. <i>Expert Review of Anti-Infective Therapy</i> , 2012, 10, 597-612.	4.4	14
117	Cestodes. , 2012, , 2052-2057.		0
118	Efficacy of Diverse Antiparasitic Treatments for Cysticercosis in the Pig Model. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 87, 292-296.	1.4	43
119	Edema surrounding calcified intracranial cysticerci: clinical manifestations, natural history, and treatment. <i>Pathogens and Global Health</i> , 2012, 106, 275-279.	2.3	44
120	Neurocysticercosis in sub-Saharan Africa: a review of prevalence, clinical characteristics, diagnosis, and management. <i>Pathogens and Global Health</i> , 2012, 106, 261-274.	2.3	88
121	Current status and future perspectives on the medical treatment of neurocysticercosis. <i>Pathogens and Global Health</i> , 2012, 106, 305-309.	2.3	16

#	ARTICLE	IF	CITATIONS
122	Prévention et traitement de la cysticercose. Journal Des Anti-infectieux, 2012, 14, 143-150.	0.1	3
123	Reduced percentage of neurocysticercosis cases among patients with late-onset epilepsy in the new millennium. Clinical Neurology and Neurosurgery, 2012, 114, 1254-1256.	1.4	7
124	Cestode Infestations. Infectious Disease Clinics of North America, 2012, 26, 421-435.	5.1	79
125	Three-day versus 15-day course of albendazole therapy in solitary cysticercus granuloma: An open label randomized trial. Journal of the Neurological Sciences, 2012, 316, 36-41.	0.6	7
126	Infection and inflammation. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 108, 601-620.	1.8	5
127	Neglected Infections of Poverty in Texas and the Rest of the United States: Management and Treatment Options. Clinical Pharmacology and Therapeutics, 2012, 92, 170-181.	4.7	15
129	Neurocysticercosis: A Review. Scientific World Journal, The, 2012, 2012, 1-8.	2.1	142
130	An acquired source of seizures. BMJ, The, 2012, 344, e2991-e2991.	6.0	4
131	Neurocysticercosis in Immigrant Populations. Journal of Travel Medicine, 2012, 19, 73-75.	3.0	16
132	NEUROCYSTICERCOSIS in Pregnancy. Nursing for Women's Health, 2012, 16, 118-124.	0.8	9
133	Neurocysticercosis: is serology useful in the absence of brain imaging?. Tropical Medicine and International Health, 2012, 17, 1014-1018.	2.3	37
134	Immune responses to viable and degenerative metacestodes of Taenia solium in naturally infected swine. International Journal for Parasitology, 2013, 43, 1101-1107.	3.1	29
135	From seizures to epilepsy and its substrates: neurocysticercosis. Epilepsia, 2013, 54, 783-792.	5.1	88
136	Neurocysticercosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 114, 313-325.	1.8	31
137	Clinical characteristics, risk factors and presurgical evaluation of postinfectious epilepsy. European Journal of Neurology, 2013, 20, 429-439.	3.3	22
138	Corticosteroids for neurocysticercosis: a systematic review and meta-analysis of randomized controlled trials. International Journal of Infectious Diseases, 2013, 17, e583-e592.	3.3	17
139	Neurocysticercosis. Neurology: Clinical Practice, 2013, 3, 118-125.	1.6	53
140	Drug therapy for solitary cysticercus granuloma. Neurology, 2013, 80, 152-162.	1.1	63

#	ARTICLE	IF	CITATIONS
141	Evidence-based guideline: Treatment of parenchymal neurocysticercosis [RETIRED]. <i>Neurology</i> , 2013, 80, 1424-1429.	1.1	119
142	Neurocysticercosis in a European Traveler Returning From India Primarily Suspected as Neoplasia. <i>Journal of Travel Medicine</i> , 2013, 20, 333-335.	3.0	5
143	Epilepsy in sub-Saharan Africa. <i>Practical Neurology</i> , 2013, 13, 14-20.	1.1	16
144	Neurocysticercosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 710-713.	0.8	8
145	Neurocisticercose em tronco cerebral: relato de caso e revisÃ£o da literatura. <i>Brazilian Neurosurgery</i> , 2013, 32, 262-264.	0.1	0
146	Epilepsy and Neurocysticercosis in Sub-Saharan Africa. , 0, , .		2
147	Control of Taenia Solium Transmission of Taeniosis and Cysticercosis in Endemic Countries: The Roles of Continental Networks of Specialists and of Local Health Authorities. , 2013, , .		4
148	The relationship between neurocysticercosis and epilepsy: an endless debate. <i>Arquivos De Neuro-Psiquiatria</i> , 2014, 72, 383-390.	0.8	39
149	Neurocysticercosis: Clinical Aspects, Immunopathology, Diagnosis, Treatment and Vaccine Development. <i>Epidemiology (Sunnyvale, Calif)</i> , 2014, 04, .	0.3	1
150	Parasitic diseases in travelers: a focus on therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 497-521.	4.4	5
151	Neurocysticercosis. <i>Neurohospitalist, The</i> , 2014, 4, 205-212.	0.8	33
152	Three Cases of Imported Neurocysticercosis in Northern Italy. <i>Journal of Travel Medicine</i> , 2014, 21, 17-23.	3.0	8
153	Neurocysticercosis: Neurology and Neurobiology. , 2014, , 127-146.		1
154	Parasitosis del sistema nervioso central: neurocisticercosis, hidatidosis, neuroesquistosomiasis, toxoplasmosis y tripanosomiasis americana. , 2014, , 253-288.		0
155	Management of Neurocysticercosis. , 2014, , 109-123.		0
156	Other Cestode Infections. , 2014, , 820-832.e1.		7
157	Taeniosis and Cysticercosis. , 2014, , 201-227.		1
159	Neurocysticercosis. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014, 121, 1445-1459.	1.8	49

#	ARTICLE	IF	CITATIONS
161	Helminth Infections and their Impact on Global Public Health. , 2014, , .		14
162	Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: A reason for the variable efficacy of albendazole and praziquantel?. Journal of Clinical Pharmacology, 2014, 54, 361-367.	2.0	12
163	Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurology, The, 2014, 13, 1202-1215.	10.2	408
164	Neurocysticercosis: An Update. Current Infectious Disease Reports, 2014, 16, 437.	3.0	17
165	Determining better treatments for neurocysticercosis. Lancet Infectious Diseases, The, 2014, 14, 658-659.	9.1	2
166	Immunology of <i>Taenia solium</i> taeniasis and human cysticercosis. Parasite Immunology, 2014, 36, 388-396.	1.5	50
167	Enhanced steroid dosing reduces seizures during antiparasitic treatment for cysticercosis and early after. Epilepsia, 2014, 55, 1452-1459.	5.1	51
168	Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infectious Diseases, The, 2014, 14, 687-695.	9.1	149
169	Clinical management of neurocysticercosis. Expert Review of Neurotherapeutics, 2014, 14, 389-396.	2.8	25
170	Clinical profile and outcome of pediatric neurocysticercosis: A study from Western Nepal. Journal of Pediatric Neurology, 2015, 05, 045-052.	0.2	5
172	Neurocysticercosis: An uncommon cause of drugâ€refractory epilepsy in North Indian population. Epilepsia, 2015, 56, 1747-1752.	5.1	14
173	Conservative management of neurocysticercosis in a patient with hematopoietic stem cell transplantation: a case report and review. Transplant Infectious Disease, 2015, 17, 456-462.	1.7	10
174	Managing neurocysticercosis: challenges and solutions. International Journal of General Medicine, 2015, 8, 333.	1.8	33
176	Tapeworms (Cestodes). , 2015, , 3227-3236.e1.		1
177	Disseminated neurocysticercosis: stars beyond the sky. BMJ Case Reports, 2015, 2015, bcr2015212401.	0.5	4
178	The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 738-746.	1.8	33
179	Immune response to Taenia solium cysticerci after anti-parasitic therapy. International Journal for Parasitology, 2015, 45, 749-759.	3.1	18
180	Neurocysticercosis in pregnancy: maternal and fetal outcomes. Oxford Medical Case Reports, 2016, 2016, 138-140.	0.4	9

#	ARTICLE	IF	CITATIONS
181	Benzimidazoles. , 2016, , 849-856.		0
182	Albendazole and Corticosteroids for the Treatment of Solitary Cysticercus Granuloma: A Network Meta-analysis. PLoS Neglected Tropical Diseases, 2016, 10, e0004418.	3.0	39
183	A large silent cysticercus occupying most of the medulla oblongata. European Journal of Neurology, 2016, 23, e6-7.	3.3	0
184	Neurocysticercosis with Diplopia Responds Well to Albendazole. Internal Medicine, 2016, 55, 1219-1222.	0.7	2
185	Disseminated cysticercosis. Medicine (United States), 2016, 95, e4882.	1.0	26
186	Update on the Diagnosis and Management of Neurocysticercosis. Current Infectious Disease Reports, 2016, 18, 44.	3.0	30
187	Neurocysticercosis in Bhutan: a cross-sectional study in people with epilepsy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 517-526.	1.8	13
188	Pathogenesis of <i>Taenia solium</i> taeniasis and cysticercosis. Parasite Immunology, 2016, 38, 136-146.	1.5	49
189	Cysticidal Efficacy of Combined Treatment With Praziquantel and Albendazole for Parenchymal Brain Cysticercosis. Clinical Infectious Diseases, 2016, 62, 1375-1379.	5.8	59
190	Recent advances and perspectives in molecular epidemiology of <i>Taenia solium</i> cysticercosis. Infection, Genetics and Evolution, 2016, 40, 357-367.	2.3	37
191	Seroprevalence and risk factors of human cysticercosis and taeniasis prevalence in a highly endemic area of epilepsy in Bangoua, west Cameroon. Acta Tropica, 2017, 165, 116-120.	2.0	15
192	Screening, diagnosis and management of human cysticercosis and <i>Taenia solium</i> taeniasis: technical recommendations by the COHEMI project study group. Tropical Medicine and International Health, 2017, 22, 881-894.	2.3	23
193	Needs of exploring the burden of recent onset seizures due to neurocysticercosis and challenges in southeast Asia focusing on scenario in Malaysia. Asian Pacific Journal of Tropical Medicine, 2017, 10, 332-340.	0.8	4
194	Antiparasitic treatment of neurocysticercosis - The effect of cyst destruction in seizure evolution. Epilepsy and Behavior, 2017, 76, 158-162.	1.7	25
195	Adhesion molecules, chemokines and matrix metallo-proteinases response after albendazole and albendazole plus steroid therapy in swine neurocysticercosis. Experimental Parasitology, 2017, 182, 1-8.	1.2	6
196	Clinical presentation of neurocysticercosis-related epilepsy. Epilepsy and Behavior, 2017, 76, 151-157.	1.7	14
197	Evaluation of imaging patterns of extra-cranial cysticercosis in North India. Radiology of Infectious Diseases, 2017, 4, 49-57.	0.0	1
198	Controversies in the treatment of seizures associated with neurocysticercosis. Epilepsy and Behavior, 2017, 76, 163-167.	1.7	9

#	ARTICLE	IF	CITATIONS
199	Report of three imported cases of neurocysticercosis in Guadeloupe. BMC Infectious Diseases, 2017, 17, 106.	2.9	2
200	Neurocysticercosis: a review on status in India, management, and current therapeutic interventions. Parasitology Research, 2017, 116, 21-33.	1.6	15
201	Antiparasitic Agents. , 2017, , 1345-1372.e2.		15
202	Disease Centered Around Calcified Taenia solium Granuloma. Trends in Parasitology, 2017, 33, 65-73.	3.3	29
204	Infectious Causes of Epilepsy: Cysticercosis in South America. , 0, , 25-29.		0
205	Disseminated cysticercosis and role of spin echo short tau inversion recovery sequence imaging: Case based review. International Journal of Epilepsy, 2017, 04, 174-180.	0.5	0
206	Helminthic Diseases: Taeniasis and Cysticercosis due to Taenia solium. , 2017, , 597-603.		1
207	Identification and characterization of Taenia solium enolase as a plasminogen-binding protein. Acta Tropica, 2018, 182, 69-79.	2.0	19
208	Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clinical Infectious Diseases, 2018, 66, e49-e75.	5.8	134
209	Neurocysticercosis: the good, the bad, and the missing. Expert Review of Neurotherapeutics, 2018, 18, 289-301.	2.8	36
210	Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)1. Clinical Infectious Diseases, 2018, 66, 1159-1163.	5.8	100
211	The effect of albendazole treatment on non-seizure outcomes in patients with symptomatic neurocysticercosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2018, 112, 73-80.	1.8	5
212	Taenia solium, Taenia asiatica, and Taenia saginata. , 2018, , 1397-1404.e4.		1
213	Taeniasis and Cysticercosis. , 2018, , 217-243.		0
214	Screening for neurocysticercosis in internationally adopted children: yield, cost and performance of serological tests, Italy, 2001 to 2016. Eurosurveillance, 2018, 23, .	7.0	6
215	Neurocysticercosis. Neurologic Clinics, 2018, 36, 851-864.	1.8	65
216	Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). American Journal of Tropical Medicine and Hygiene, 2018, 98, 945-966.	1.4	90
217	Updates on the management of neurocysticercosis. Current Opinion in Infectious Diseases, 2018, 31, 377-382.	3.1	14

#	ARTICLE	IF	CITATIONS
218	Neurocysticercosis in Children with Seizures: A Cross-Sectional Study. <i>International Journal of Pediatrics (United Kingdom)</i> , 2018, 2018, 1-6.	0.8	5
219	Comparison of telephone with face to face consultation for follow up of Neurocysticercosis. <i>Epilepsy Research</i> , 2018, 145, 110-115.	1.6	10
220	Human taeniasis/cysticercosis: a potentially emerging parasitic disease in Europe. <i>Annals of Gastroenterology</i> , 2018, 31, 406-412.	0.6	35
221	Neurological Syndromes or Diseases Caused by Parasites in Tropical Areas. , 2018, , 233-246.		0
222	Predictors of unprovoked seizures in surgically treated pyogenic brain abscess: Does perioperative adjunctive use of steroids has any protective effect?. <i>Clinical Neurology and Neurosurgery</i> , 2018, 173, 46-51.	1.4	7
223	High prevalence of taeniasis and <i>Taenia solium</i> cysticercosis in children in western Sichuan, China. <i>Acta Tropica</i> , 2019, 199, 105133.	2.0	20
224	Parasitic Infections of the Nervous System. <i>Seminars in Neurology</i> , 2019, 39, 358-368.	1.4	9
225	A Large Cohort of Neurocysticercosis in Shandong Province, Eastern China, 1997â€“2015. <i>Vector-Borne and Zoonotic Diseases</i> , 2019, 19, 901-907.	1.5	6
226	Exploring the complex associations over time among albendazole treatment, cyst evolution, and seizure outcomes in neurocysticercosis. <i>Epilepsia</i> , 2019, 60, 1820-1828.	5.1	17
227	Sample size calculation for clinical trials with correlated count measurements based on the negative binomial distribution. <i>Statistics in Medicine</i> , 2019, 38, 5413-5427.	1.6	5
228	A longitudinal analysis of albendazole treatment effect on neurocysticercosis cyst evolution using multistate models. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2019, 113, 781-788.	1.8	11
229	Neurocysticercosis. <i>Infectious Disease Clinics of North America</i> , 2019, 33, 153-168.	5.1	18
230	Neurocysticercosis and HIV Infection: what can we learn from the published literature?. <i>Arquivos De Neuro-Psiquiatria</i> , 2019, 77, 357-365.	0.8	10
231	Epilepsy Associated with Neurocysticercosis. , 2019, , 632-637.		0
232	Considering Over-Dispersion in the Sample Size Calculation for Clinical Trials With Repeated Count Measurements. <i>Statistics in Biopharmaceutical Research</i> , 2019, 11, 283-291.	0.8	0
233	Seizures and Epilepsy. , 2019, , 9-46.		7
234	Hydrocephalus in Neurocysticercosis: Challenges for Clinical Practice and Basic Research Perspectives. <i>World Neurosurgery</i> , 2019, 126, 264-271.	1.3	13
235	Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	29

#	ARTICLE	IF	CITATIONS
236	Modifiable environmental factors – Role and impact of (including evidence for intervention). Journal of the Neurological Sciences, 2019, 405, 23.	0.6	0
237	Comorbidities – Impact on disease evolution, progression and treatment response. Journal of the Neurological Sciences, 2019, 405, 23-24.	0.6	0
238	Neurocysticercosis and epilepsy: Diagnosis, treatment and prevention. Journal of the Neurological Sciences, 2019, 405, 22-23.	0.6	0
239	Diagnosis and Management of Neurocysticercosis: Will Real-time Polymerase Chain Reaction Help?. Clinical Infectious Diseases, 2020, 70, 1882-1883.	5.8	1
240	Do albendazole-loaded lipid nanocapsules enhance the bioavailability of albendazole in the brain of healthy mice?. Acta Tropica, 2020, 201, 105215.	2.0	8
241	Newer magnetic resonance imaging techniques in neurocysticercosis. Neuroradiology Journal, 2020, 33, 538-544.	1.2	4
242	Brain calcification because of neurocysticercosis: a vast field to be explored. Current Opinion in Infectious Diseases, 2020, 33, 334-338.	3.1	10
243	Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	17
244	Zoonotic and vector-borne parasites and epilepsy in low-income and middle-income countries. Nature Reviews Neurology, 2020, 16, 333-345.	10.1	19
245	Taenia solium Cysticercosis and Its Impact in Neurological Disease. Clinical Microbiology Reviews, 2020, 33, .	13.6	61
246	Neurocysticercosis-related seizures in the post-partum period: two cases and a review of the literature. Lancet Infectious Diseases, The, 2020, 20, e204-e214.	9.1	4
247	Frequency and Determinant Factors for Calcification in Neurocysticercosis. Clinical Infectious Diseases, 2021, 73, e2592-e2600.	5.8	24
248	Quantitative assessment of lesion load and efficacy of 3 cycles of albendazole in disseminated cysticercosis: a prospective evaluation. BMC Infectious Diseases, 2020, 20, 220.	2.9	11
249	New Insights Into Calcified Neurocysticercosis: Closing the Knowledge Gap. Clinical Infectious Diseases, 2021, 73, e2601-e2603.	5.8	3
250	A multistate joint model for interval-censored event history data subject to within-unit clustering and informative missingness, with application to neurocysticercosis research. Statistics in Medicine, 2020, 39, 3195-3206.	1.6	3
251	Current approaches to cysticidal drug therapy for neurocysticercosis. Expert Review of Anti-Infective Therapy, 2020, 18, 789-798.	4.4	8
252	–Malignant–Craniospinal Neurocysticercosis: A Rare Case. World Neurosurgery, 2021, 146, 95-102.	1.3	1
253	Calcified Neurocysticercosis: The Knowledge Gap Remains. Clinical Infectious Diseases, 2021, 72, e688-e689.	5.8	0

#	ARTICLE	IF	CITATIONS
254	A Clinical Prognostic Scoring System for Neurocysticercosis. <i>Journal of Neurosciences in Rural Practice</i> , 2021, 12, 39-45.	0.8	0
255	Taeniasis and Cysticercosis. <i>Neglected Tropical Diseases</i> , 2021, , 47-67.	0.4	0
256	Recurrent Neurocysticercosis: Not So Rare. <i>Neurology India</i> , 2021, 69, 385.	0.4	0
257	Cysticidal Therapy for Diffuse Parenchymal and Calcific Neurocysticercosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 734-738.	1.4	3
258	The effectiveness of anti-inflammatory and anti-seizure medication for individuals with single enhancing lesion neurocysticercosis: A meta-analysis and expert group-based consensus recommendations. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009193.	3.0	8
259	Anthelmintics for people with neurocysticercosis. <i>The Cochrane Library</i> , 2021, 2021, CD000215.	2.8	12
260	Mortality in Parenchymal and Subarachnoid Neurocysticercosis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 176-180.	1.4	8
261	New understanding about the relationship among neurocysticercosis, seizures, and epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021, 90, 123-129.	2.0	12
262	Neurocysticercosis. A frequent cause of seizures, epilepsy, and other neurological morbidity in most of the world. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117527.	0.6	15
263	Parasitic Infections of the Nervous System. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2021, 27, 943-962.	0.8	7
264	A bias correction method in meta-analysis of randomized clinical trials with no adjustments for zero-inflated outcomes. <i>Statistics in Medicine</i> , 2021, 40, 5894-5909.	1.6	4
265	Infections of the Nervous System. , 2012, , 293-320.		1
266	Cysticercosis: A Preventable, but Embarrassing Neglected Disease Still Prevalent in Non-Developed Countries. , 2015, , 335-354.		3
267	Parasitic Infections. , 2010, , 1751-1768.		1
268	Cestodes (Tapeworms). , 2010, , 3607-3616.		7
269	Systemic Parasitic Infections and the Eye. , 2008, , 4751-4773.		1
270	Albendazole Sulfoxide Plasma Levels and Efficacy of Antiparasitic Treatment in Patients With Parenchymal Neurocysticercosis. <i>Clinical Infectious Diseases</i> , 2019, 69, 1996-2002.	5.8	11
271	Under seize: neurocysticercosis in an immigrant woman and review of a growing neglected disease. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015212839.	0.5	4

#	ARTICLE	IF	CITATIONS
273	Helminthic Infections of the Central Nervous System. CONTINUUM Lifelong Learning in Neurology, 2018, 24, 1489-1511.	0.8	5
274	Optimizing therapy of seizures in patients with HIV and cysticercosis. Neurology, 2006, 67, S19-22.	1.1	15
275	Serological Studies of Neurologic Helminthic Infections in Rural Areas of Southwest Cameroon: Toxocariasis, Cysticercosis and Paragonimiasis. PLoS Neglected Tropical Diseases, 2010, 4, e732.	3.0	28
276	Radiological evolution of porcine neurocysticercosis after combined antiparasitic treatment with praziquantel and albendazole. PLoS Neglected Tropical Diseases, 2017, 11, e0005624.	3.0	7
277	Neurocysticercosis Involving the Pituitary Stalk : Case Report and Literature Review. Journal of Korean Neurosurgical Society, 2010, 48, 91.	1.2	11
278	Seroprevalence of antibodies (IgG) to Taenia solium among pig rearers and associated risk factors in Jos metropolis, Nigeria. Journal of Infection in Developing Countries, 2013, 7, 067-072.	1.2	28
280	Neurocysticercosis: Diagnostic problems & current therapeutic strategies. Indian Journal of Medical Research, 2016, 144, 319.	1.0	35
281	Effects of albendazole administration on the testicular histology of adult Wistar rats. Journal of Experimental and Clinical Anatomy, 2013, 12, 50.	0.2	1
282	Starry sky appearance. Current Medical Issues, 2019, 17, 45.	0.2	2
283	Fourth ventricle neurocysticercosis: A case report. , 2018, 9, 201.		6
284	A Personal Account Regarding the Origin and Evolution of Controversies in the Management of Neurocysticercosis. American Journal of Tropical Medicine and Hygiene, 2019, 100, 780-782.	1.4	7
285	Case Report: Subarachnoid Hemorrhage and Eosinophilic Meningitis due to Disseminated Fascioliasis. American Journal of Tropical Medicine and Hygiene, 2020, 102, 574-577.	1.4	2
286	Unique Characteristics of Epilepsy Development in Neurocysticercosis. American Journal of Tropical Medicine and Hygiene, 2020, 103, 639-645.	1.4	19
287	Optimal Treatment for Subarachnoid Neurocysticercosis: Closer, but Not There yet. American Journal of Tropical Medicine and Hygiene, 2020, 102, 1-2.	1.4	2
288	NEW CONCEPTS IN THE DIAGNOSIS AND MANAGEMENT OF NEUROCYSTICERCOSIS (TAENIA SOLIUM). American Journal of Tropical Medicine and Hygiene, 2005, 72, 3-9.	1.4	149
289	Contemporary Neurosurgical Approaches to Neurocysticercosis. American Journal of Tropical Medicine and Hygiene, 2009, 80, 373-378.	1.4	62
290	Urine Antigen Detection for the Diagnosis of Human Neurocysticercosis. American Journal of Tropical Medicine and Hygiene, 2009, 80, 379-383.	1.4	30
291	Recently Reemerging Helminthic Infections Causing Eosinophilic Meningoencephalitis: Neuroangiostrongyliasis, Baylisascariasis, and~Gnathostomiasis. Journal of Neuroparasitology, 2010, 1, 1-14.	0.6	2

#	ARTICLE	IF	CITATIONS
293	Neurocysticercose. Revista Neurociencias, 2010, 18, 581-594.	0.0	0
294	Cerebral Cysticercosis and Seizures. Pediatric Neurology Briefs, 2004, 18, 7.	0.2	0
296	Gastro-Intestinal Helminths And Public Health:: Overview Of A Neglected Sector. The Internet Journal of Veterinary Medicine, 2008, 4, .	0.1	1
297	Helminth Infections. , 2008, , 349-376.		0
298	Taenia solium and Taenia saginala (Taeniasis and Cysticercosis). , 2008, , 1321-1327.		1
299	PROTOZOAN AND HELMINTHIC INFECTIONS. , 2009, , 1171-1186.		1
300	CESTODES. , 2009, , 2996-3015.		0
301	Cestode and trematode infections. , 2010, , 1177-1181.		0
302	ANTIPROTOZOAL AND ANTIHELMINTHIC DRUGS. , 2010, , 777-932.		1
304	Educating People Participating in the Pig Industry to Reduce Epilepsy due to Taenia Solium. , 0, , .		1
305	Infektionen. , 2012, , 483-550.		0
306	Taenia solium, Taenia asiatica, and Taenia saginata (Taeniasis and Cysticercosis). , 2012, , 1350-1356.e6.		0
308	Epilepsies. , 2012, , 1583-1633.		1
309	Mixed cestode infection: an incidental association in an immunocompetent person. BMJ Case Reports, 2012, 2012, bcr2012007640-bcr2012007640.	0.5	0
311	Neurocysticercosis and Epilepsy. , 0, , .		2
312	NEUROCYSTICERCOSIS WITH A SPACE OCCUPYING LESION: A CASE STUDY. Journal of Evolution of Medical and Dental Sciences, 2014, 3, 4488-4490.	0.1	0
313	Infektionen. , 2015, , 505-575.		0
314	ROLE OF CT IN THE STUDY OF PREVALENCE OF NEUROCYSTICERCOSIS IN A RURAL AND SUBURBAN TEACHING HOSPITAL. Journal of Evidence Based Medicine and Healthcare, 2016, 3, 3476-3481.	0.0	0

#	ARTICLE	IF	CITATIONS
315	Parasitic Infections. , 2017, , .		0
316	Neurocysticercosis among People Living Near Pigs Heavily Infected with Cysticercosis in Rural Endemic Peru. American Journal of Tropical Medicine and Hygiene, 2018, 98, 558-564.	1.4	4
317	Pediatric Tuberculosis and Parasitic and Fungal Infections. , 2019, , 1-29.		0
318	Neurocysticercosis and Other CNS Helminthic Infections. Current Clinical Neurology, 2021, , 225-254.	0.2	2
319	Cysticercosis. , 2020, , 1533-1539.		0
320	Pediatric Tuberculosis and Parasitic and Fungal Infections. , 2020, , 1751-1771.		0
321	Seizures in Pregnancy- A Rare Case of Neurocysticercosis Mimicking Eclampsia. Journal of Evolution of Medical and Dental Sciences, 2020, 9, 1012-1014.	0.1	0
323	Bandwurminfektionen (Zestoden). , 2006, , 351-361.		0
324	Case Report: Three Cases of Neurocysticercosis in Central Africa. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1955-1957.	1.4	2
325	Neuro and intraocular cysticercosis: A clinicopathological case report. Eye and Brain, 2010, 2, 39-42.	2.5	6
326	Calcified neurocysticercosis lesions trigger symptomatic inflammation during antiparasitic therapy. American Journal of Neuroradiology, 2006, 27, 653-5.	2.4	21
327	Neurocysticercosis in Children. Pediatric Clinics of North America, 2022, 69, 115-127.	1.8	1
328	Improved diagnosis of viable parenchymal neurocysticercosis by combining antibody banding patterns on enzyme-linked immunoelectrotransfer blot (EITB) with antigen ELISA assay. Journal of Clinical Microbiology, 2021, , JCM0155021.	3.9	5
330	Epilepsy due to Neurocysticercosis: Analysis of a Hospital Cohort. Journal of Neuroscience and Neurological Disorders, 2020, 4, 063-068.	0.3	0
331	Disseminated cysticercosis: a case report and review of treatment protocols. BMJ Case Reports, 2022, 15, e248603.	0.5	0
332	Epileptogenesis in Common Parasitic Infections. Current Neurology and Neuroscience Reports, 2022, 22, 285-291.	4.2	3
335	Systemic Parasitic Infections and the Eye. , 2022, , 7369-7408.		0
336	Quality of life in patients with symptomatic epilepsy due to neurocysticercosis. Epilepsy and Behavior, 2022, 131, 108668.	1.7	1

#	ARTICLE	IF	CITATIONS
337	Intraventricular neurocysticercosis causing obstructing hydrocephalus. Baylor University Medical Center Proceedings, 2022, 35, 722-724.	0.5	1
338	Neurocysticercosis: an update on diagnosis, treatment, and prevention. Current Opinion in Infectious Diseases, 2022, 35, 246-254.	3.1	3
339	Neurocysticercosis Complicating Pregnancy. Obstetrics and Gynecology, 2022, Publish Ahead of Print, .	2.4	1
340	Update on the diagnosis and management of neurocysticercosis. Arquivos De Neuro-Psiquiatria, 2022, 80, 296-306.	0.8	9
341	Taeniasis and Cysticercosis. , 2022, , 313-349.		0
342	Cysticercosis. , 2022, , 1-28.		0
343	Neurocysticercosis in the Tropics (and Beyond). Current Tropical Medicine Reports, 0, , .	3.7	0
344	Clinical characteristics and management of neurocysticercosis patients: a retrospective assessment of case reports from Europe. Journal of Travel Medicine, 2023, 30, .	3.0	9
345	Human Neurocysticercosis: An Overview. Pathogens, 2022, 11, 1212.	2.8	15
346	Common infectious and parasitic diseases as a cause of seizures: geographic distribution and contribution to the burden of epilepsy. Epileptic Disorders, 2022, 24, 994-1019.	1.3	6
347	Antiparasitic Agents. , 2023, , 1598-1617.e2.		1
348	Taenia solium, Taenia asiatica, and Taenia saginata. , 2023, , 1435-1442.e5.		0
349	THE EFFICACY AND SAFETY OF THREE 30-DAY COURSES OF ALBENDAZOLE IN PATIENTS WITH NEUROCYSTICERCOSIS. Russian Journal of Infection and Immunity, 0, , .	0.7	0
350	What Causes Seizures in Neurocysticercosis?. Epilepsy Currents, 2023, 23, 105-112.	0.8	3
351	Systemic Parasitic Infections and the Eye. , 2021, , 1-40.		0
352	Efficacy and safety of antiparasitic therapy for neurocysticercosis in rural Tanzania: a prospective cohort study. Infection, 0, , .	4.7	1
353	Neurocysticercosis: A Review on Global Neurological Disease. Infectious Diseases, 0, , .	4.0	1
354	Neurocysticercosis-related seizures: Imaging biomarkers. Seizure: the Journal of the British Epilepsy Association, 2023, 108, 13-23.	2.0	1

#	ARTICLE	IF	CITATIONS
355	Other Cestode Infections: Intestinal Cestodes, Cysticercosis, Other Larval Cestode Infections. , 2024, , 822-833.		0
356	Triggered: Discovery of Neurocysticercosis Following Self-Administered Albendazole. Cureus, 2023, , .	0.5	0
357	Cysticercosis. , 2023, , 475-501.		0
358	Helminthic diseases: Taeniasis and cysticercosis due to Taenia solium. , 2023, , .		0
359	Incident Breakthrough Seizures, Serum Matrix Metalloproteinase-9 and Perfusion Magnetic Resonance Imaging Parameters in a Cohort of Children and Adolescents With Neurocysticercosis: A Longitudinal Observational Study. Pediatric Neurology, 2024, 151, 45-52.	2.1	0
361	Top-50 cited articles on cysticercosis and neurocysticercosis. Medicine (United States), 2024, 103, e37268.	1.0	0